1-phenyl-2-decanoylamino-3-morpholino-1-propanol has been researched along with Atherosclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, Y; Deng, J; Hao, H; Huang, Y; Li, S; Meng, L; Nan, D; Peng, Q; Shen, Z; Yu, W; Yu, Z | 1 |
| Amuzie, C; Bedja, D; Bhattacharya, R; Chatterjee, S; Foss, CA; Mishra, S; Pomper, MG; Yarema, KJ | 1 |
2 other study(ies) available for 1-phenyl-2-decanoylamino-3-morpholino-1-propanol and Atherosclerosis
| Article | Year |
|---|---|
Myriocin and d-PDMP ameliorate atherosclerosis in ApoE-/- mice via reducing lipid uptake and vascular inflammation.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Atherosclerosis; Atorvastatin; Biological Transport; Ceramides; Fatty Acids, Monounsaturated; Glycosphingolipids; Immunosuppressive Agents; Lipid Metabolism; Lipids; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Plaque, Atherosclerotic; Vasculitis | 2020 |
Improved intervention of atherosclerosis and cardiac hypertrophy through biodegradable polymer-encapsulated delivery of glycosphingolipid inhibitor.
Topics: Animals; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Capsules; Cardiomegaly; Cholesterol, Dietary; Decanoic Acids; Delayed-Action Preparations; Dicarboxylic Acids; Diet, Atherogenic; Drug Evaluation, Preclinical; Heart Ventricles; Inactivation, Metabolic; Iodine Radioisotopes; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Structure; Morpholines; Nanoparticles; Polyethylene Glycols; Tissue Distribution; Vascular Stiffness | 2015 |